VTGN

VistaGen Therapeutics, Inc.

0.25 USD

Last updated Sep 5, 10:39 UTC

Yesterday HIGH

$0.26

Yesterday LOW

$0.24

52w HIGH

$5.14

52w LOW

$0.2

EPS

-0.30

PE

-0.84

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

VistaGen Therapeutics, Inc. stock is down -9.77% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 12 September’s closed higher than August.

Benzinga Newsdesk

Tue Jun 30, 2026

Vistagen Therapeutics shares are trading lower after the company announced topline results from the PALISADE-4 Phase 3 trial. Fasedienol did not achieve its primary endpoint and there was no treatment difference between fasedienol and the placebo for the secondary endpoints.
Webmaster

Tue Jun 30, 2026

Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Tue Jun 30, 2026

Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint

PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in reducing anxiety
Webmaster

Tue Jun 30, 2026

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Tue Jun 16, 2026

Vistagen Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results.
Benzinga Newsdesk

Mon Jun 15, 2026

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per
Benzinga Newsdesk

Tue May 12, 2026

Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
Benzinga Newsdesk

Fri May 8, 2026

Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
Benzinga Newsdesk

Wed Apr 22, 2026

Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
Benzinga Insights

Tue Apr 14, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

LLY $1,148.68 USD

MCD $255.68 USD

TGTX $56.00 USD

NCLH $15.56 USD

LKNCY $0.00 USD

NFLX $78.29 USD

ETH ETH $23.42 USD